Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Status:
Completed
Trial end date:
2015-01-19
Target enrollment:
Participant gender:
Summary
Study WCMC IST/VOS/MDS evaluates the safety and tolerability of escalating doses of vosaroxin
in adult patients with pathologically confirmed Myelodysplastic Syndrome, or MDS, (< 20%
blasts in bone marrow, peripheral blood, or both) by World Health Organization (WHO)
classification with an intermediate 2 (INT-2) or high-risk score (ie, ≥ 1.5) as assessed by
the International Scoring System (IPSS) after failure of hypomethylating agent-based therapy.
Based on 3 completed studies and xenograft models, Vosaroxin is hypothesized to be safe and
will effective in this patient population.